Pfizer’s (PFE) shares rose over 2% early Tuesday after the American pharma giant released first-quarter 2026 earnings results that surpassed the Wall Street consensus. This comes even as Pfizer maintained its $59.5 to $62.5 billion sales forecast for fiscal 2026 — a range lower than its 2025 performance and below analysts’ consensus at the midpoint.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
During the three-month period, Pfizer grew its revenue by 5% from a year ago to $14.5 billion, well ahead of the Wall Street estimate of $13.8 billion. Its adjusted earnings per share came in at $0.75, down 18% year-over-year but topping the $0.72 analysts had expected.